Trials / Active Not Recruiting
Active Not RecruitingNCT04764188
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alectinib | Participants will receive alectinib in accordance with local clinical practice and local labeling. |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2027-05-10
- Completion
- 2027-05-10
- First posted
- 2021-02-21
- Last updated
- 2026-04-13
Locations
116 sites across 25 countries: Argentina, Australia, Austria, Belgium, Bulgaria, Chile, China, Colombia, Croatia, Cuba, Czechia, Finland, Israel, Italy, Lithuania, Panama, Peru, Portugal, Romania, Russia, Serbia, Turkey (Türkiye), United Arab Emirates, Uruguay, Vietnam
Source: ClinicalTrials.gov record NCT04764188. Inclusion in this directory is not an endorsement.